NRSN
NASDAQ · Biotechnology
Neurosense Therapeutics Ltd
$5.10
-1.85 (-26.62%)
Open$6.60
Previous Close$6.95
Day High$7.15
Day Low$4.93
52W High$26.64
52W Low$5.00
Volume—
Avg Volume18.4K
Market Cap14.04M
P/E Ratio—
EPS$-12.44
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+590.8% upside
Current
$5.10
$5.10
Target
$35.23
$35.23
$27.84
$35.23 avg
$57.14
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.58M | 1.62M | 1.28M |
| Net Income | 134.3K | 163.7K | 131.8K |
| Profit Margin | 8.5% | 10.1% | 10.3% |
| EBITDA | 233.3K | 224.5K | 177.5K |
| Free Cash Flow | 149.0K | 201.8K | 175.9K |
| Rev Growth | +15.5% | +19.0% | +13.7% |
| Debt/Equity | 0.19 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |